{
  "JOHNSON & JOHNSON": {
    "2022": {
      "FORM": "8-K",
      "CATEGORIES": {
        "Section 5 - Corporate Governance and Management": {
          "ITEMS": {
            "Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers": {
              "content": "The information included in the third bullet under Item 5.07(b) below is incorporated herein by reference.",
              "subsections": {
                "referenced_information": "The shareholders approved the Company's 2022 Long-Term Incentive Plan (the ”2022 Plan”), which was previously approved by the Company's Board of Directors on March 7, 2022; a description of the terms and conditions of the 2022 Plan and the amounts payable thereunder is included in the 2022 Proxy Statement under \"Item 3: Approval of the Company's 2022 Long-Term Incentive Plan,” beginning on page 110 of the 2022 Proxy Statement; the description of the 2022 Plan in the 2022 Proxy Statement is qualified in its entirety by reference to the full text of the 2022 Plan, which is attached as Appendix A to the 2022 Proxy Statement."
              }
            },
            "Item 5.07 - Submission of Matters to a Vote of Security Holders": {
              "content": "The 2022 Annual Meeting of Shareholders was held on April 28, 2022.",
              "subsections": {
                "summary_of_outcomes": "At the 2022 Annual Meeting of Shareholders, the shareholders:\n• elected all 14 Director nominees named in the 2022 Proxy Statement to the Company's Board of Directors;\n• approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the “Compensation Discussion and Analysis” section of the 2022 Proxy Statement and the compensation of the Company's executive officers named in the 2022 Proxy Statement, as disclosed therein;\n• approved the Company's 2022 Long-Term Incentive Plan;\n• ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year 2022;\n• did not approve the shareholder proposal for a civil rights, equity, diversity & inclusion audit proposal;\n• approved the shareholder proposal for a third party racial justice audit;\n• did not approve the shareholder proposal for a report on government financial support and access to COVID-19 vaccines and therapeutics;\n• did not approve the shareholder proposal for a report on public health costs of protecting vaccine technology;\n• did not approve the shareholder proposal to discontinue global sales of baby powder containing talc;\n• did not approve the shareholder proposal for a request for charitable donations disclosure;\n• did not approve the shareholder proposal for a third party review and report on lobbying activities alignment with the Company's position on universal health coverage;\n• did not approve the shareholder proposal to adopt policy to include legal and compliance costs in incentive compensation metrics; and\n• did not approve the shareholder proposal for CEO compensation to weigh workforce pay and ownership.",
                "voting_results_election_of_directors": {
                  "D. Adamczyk": {
                    "For": "1,821,875,407",
                    "Against": "21,631,193",
                    "Abstain": "5,530,991",
                    "Non-Votes": "346,482,920"
                  },
                  "M. C. Beckerle": {
                    "For": "1,827,119,327",
                    "Against": "16,556,459",
                    "Abstain": "5,361,805",
                    "Non-Votes": "346,482,920"
                  },
                  "D. S. Davis": {
                    "For": "1,804,888,350",
                    "Against": "38,606,493",
                    "Abstain": "5,542,748",
                    "Non-Votes": "346,482,920"
                  },
                  "I. E. L. Davis": {
                    "For": "1,794,374,557",
                    "Against": "48,881,358",
                    "Abstain": "5,781,676",
                    "Non-Votes": "346,482,920"
                  },
                  "J. A. Doudna": {
                    "For": "1,821,404,683",
                    "Against": "22,800,923",
                    "Abstain": "4,831,985",
                    "Non-Votes": "346,482,920"
                  },
                  "J. Duato": {
                    "For": "1,835,249,999",
                    "Against": "8,652,237",
                    "Abstain": "5,135,355",
                    "Non-Votes": "346,482,920"
                  },
                  "A. Gorsky": {
                    "For": "1,744,897,480",
                    "Against": "98,478,059",
                    "Abstain": "5,662,052",
                    "Non-Votes": "346,482,920"
                  },
                  "M. A. Hewson": {
                    "For": "1,792,683,677",
                    "Against": "51,493,950",
                    "Abstain": "4,859,964",
                    "Non-Votes": "346,482,920"
                  },
                  "H. Joly": {
                    "For": "1,793,561,898",
                    "Against": "49,872,480",
                    "Abstain": "5,603,213",
                    "Non-Votes": "346,482,920"
                  },
                  "M. B. McClellan": {
                    "For": "1,695,564,934",
                    "Against": "147,919,856",
                    "Abstain": "5,552,801",
                    "Non-Votes": "346,482,920"
                  },
                  "A. M. Mulcahy": {
                    "For": "1,730,711,988",
                    "Against": "113,274,497",
                    "Abstain": "5,051,106",
                    "Non-Votes": "346,482,920"
                  },
                  "A. E. Washington": {
                    "For": "1,802,878,123",
                    "Against": "40,670,398",
                    "Abstain": "5,489,070",
                    "Non-Votes": "346,482,920"
                  },
                  "M. A. Weinberger": {
                    "For": "1,815,423,637",
                    "Against": "28,240,835",
                    "Abstain": "5,373,119",
                    "Non-Votes": "346,482,920"
                  },
                  "N. Y. West": {
                    "For": "1,834,814,211",
                    "Against": "8,991,427",
                    "Abstain": "5,231,953",
                    "Non-Votes": "346,482,920"
                  }
                },
                "voting_results_advisory_vote_on_executive_compensation": {
                  "For": "1,579,815,895",
                  "Against": "257,738,128",
                  "Abstain": "11,483,568",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_approval_of_2022_long_term_incentive_plan": {
                  "For": "1,675,020,466",
                  "Against": "165,231,757",
                  "Abstain": "8,785,368",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_ratification_of_accountant": {
                  "For": "2,041,408,099",
                  "Against": "147,081,482",
                  "Abstain": "7,030,930",
                  "Non-Votes": "N/A"
                },
                "voting_results_shareholder_proposal_civil_rights_audit": {
                  "For": "50,182,969",
                  "Against": "1,777,981,079",
                  "Abstain": "20,873,543",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_racial_justice_audit": {
                  "For": "1,144,529,241",
                  "Against": "682,570,135",
                  "Abstain": "21,938,215",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_covid_19_vaccine_access": {
                  "For": "616,715,019",
                  "Against": "1,207,732,861",
                  "Abstain": "24,589,711",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_vaccine_technology_costs": {
                  "For": "156,919,718",
                  "Against": "1,650,063,722",
                  "Abstain": "42,054,151",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_talc_baby_powder_sales": {
                  "For": "279,116,458",
                  "Against": "1,506,309,151",
                  "Abstain": "63,611,982",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_charitable_donations_disclosure": {
                  "For": "74,744,360",
                  "Against": "1,762,811,483",
                  "Abstain": "11,481,748",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_lobbying_activities_report": {
                  "For": "794,680,143",
                  "Against": "1,042,341,388",
                  "Abstain": "12,016,060",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_incentive_compensation_metrics": {
                  "For": "877,012,827",
                  "Against": "961,185,621",
                  "Abstain": "10,839,143",
                  "Non-Votes": "346,482,920"
                },
                "voting_results_shareholder_proposal_ceo_compensation_and_workforce_pay": {
                  "For": "196,312,525",
                  "Against": "1,617,183,502",
                  "Abstain": "35,541,564",
                  "Non-Votes": "346,482,920"
                }
              }
            }
          }
        }
      }
    }
  }
}